Overview

• The Advisory Committee on Immunization Practices (ACIP) has recommended RSV vaccination for at-risk adults aged 50–59, expanding its previous guidance for older age groups.
• ACIP endorsed GSK’s MenABCWY pentavalent meningococcal vaccine for individuals needing both MenACWY and MenB vaccines, simplifying dosing for adolescents and high-risk children.
• Two chikungunya vaccines were recommended: a virus-like particle vaccine for travelers and laboratory personnel, and a live attenuated vaccine with precautions for older recipients due to reported adverse events.
• A precaution was added for Valneva’s live attenuated chikungunya vaccine after six serious adverse events were reported in adults aged 65 and older, prompting further investigation.
• Formal adoption of these recommendations is delayed due to the absence of a confirmed CDC director, potentially shifting approval authority to Health Secretary Robert F. Kennedy Jr.